Quarterly ResultMay 14, 2026, 02:48 PM
XBiotech Q1 Net Loss Halved to $5.5M; Operating Expenses Down 54%
AI Summary
XBiotech Inc. reported a significant reduction in its net loss for the first quarter of 2026, halving to $5.5 million from $10.9 million in the prior year period. This improvement was driven by a substantial 53.7% decrease in total operating expenses, primarily from lower research and development costs. The company maintains a cash and cash equivalents balance of $115.5 million and anticipates having sufficient liquidity for at least the next 12 months.
Key Highlights
- Net loss decreased to $5.5 million for Q1 2026 from $10.9 million for Q1 2025.
- Net loss per share improved to $(0.18) for Q1 2026 from $(0.36) for Q1 2025.
- Total operating expenses fell 53.7% to $6.3 million for the three months ended March 31, 2026.
- Research and development expenses decreased 55.2% to $5.2 million for Q1 2026.
- General and administrative expenses decreased 44.7% to $1.1 million for Q1 2026.
- Cash and cash equivalents were $115.5 million as of March 31, 2026.
- Company expects sufficient cash to fund operations for at least 12 months.